Valvular & structural heart diseaseSecondary analysis
10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis
- Secondary analysis of the PARTNER 2A randomised trial
- multicentre
- 57 centres
- stratified by access route
- 10-year follow-up
Vital status available at 10 years for 881 of 974 transcatheter aortic valve replacement (TAVR) (90.5%) and 838 of 936 surgery (89.5%)
Authors' conclusion
At the 10-year follow-up, TAVR in intermediate-risk patients with the SAPIEN XT prosthesis compared with surgery was associated with lower survival rates, with differences predominantly observed in the TA/TAo access cohort. TAVR with the XT valve was also associated with significantly higher rates of aortic valve reintervention.
Study context
- Population
- Patients with severe, symptomatic AS at intermediate surgical riskvalve implant population
- Participants
- 1,910 patients
- Comparison
- TAVR vs surgery
- TAVRn = 974
- Surgeryn = 936reference
- Primary endpoint
- All-cause mortality
- Follow-up
- 10 years
Primary result
All-cause mortality (with vital status sweeps)
Hazard ratio
1.13
95% CI 1.02–1.25
P = 0.02
By group
As reported in the abstract
Further findings
All-cause mortality by access route (subgroup) · 10 years · TF
P = 0.27
All-cause mortality by access route (subgroup) · 10 years · TA/TAo
P < 0.01
Mean gradient (patients with echo data) · 10 years
- All-cause mortality by access route (subgroup): P for interaction = 0.03
- Mean gradient (patients with echo data): 24 TAVR and 35 surgical patients with echo data
Safety
Aortic valve reintervention (cumulative incidence) · 10 years
P < 0.001
Original publication
Summarised from the published abstract; every number is checked against it